Hepatitis C awareness among therapists and general practitioners. Survey results


Cite item

Full Text

Abstract

Aim. In order to improve the diagnosis and treatment of chronic hepatitis C in the framework of this study was the awareness among general practitioner (GPs) and physicians in various districts of Chelyabinsk Oblast was assessed.

Materials and methods. A continuous study of hepatitis C virus (HCV) awareness among therapists and GPs was conducted within the framework of the regional research-to-practice conference Multidisciplinary Issues of Family Medicine on May 19, 2018. 78 questionnaires have been distributed. Thus, 78 therapists from different districts of Chelyabinsk Oblast took part in the study. For these purposes, a questionnaire of 12 questions developed by Olga I. Sagalova was used. The study involved 78 therapists from different districts of Chelyabinsk Oblast. 20.52% (n=16) of respondents were from the healthcare institutions (HCI) of urban districts of Chelyabinsk Oblast, 39.74% (n=31) were from the HCIs of municipal districts of Chelyabinsk Oblast, and 39.74% (n=31) from the HCIs of the city of Chelyabinsk.

Results. The survey revealed certain gaps in therapists’ awareness of the natural course of the disease, diagnosis, routing, the natural course of HCV infection, as well as its extrahepatic manifestations. The survey results indicate a lack of understanding among physicians and therapists of tactics for managing patients with HCV infection and emphasize the need to improve interdisciplinary interaction between infectious disease specialists, primary care doctors and doctors of other specialties including the development and implementation of an educational strategy for non-infectious disease doctors.

Conclusion. The results indicate the needs to increase the level of education among doctors in the diagnosis and management of patients with HCV in accordance with guidelines and to include screening for HCV infection in the guidelines for selected chronic non-communicable diseases as part of the initial examination.

About the authors

A. V. Sineglazova

South Ural State Medical University

Author for correspondence.
Email: sineglazovaav@mail.ru
ORCID iD: 0000-0003-3814-7342

д.м.н., зав. инфекционным отд-нием Клиники

Russian Federation, Chelyabinsk

A. V. Sineglazova

Kazan State Medical University of the Russian Federation Ministry of Health

Email: sineglazovaav@mail.ru
ORCID iD: 0000-0002-7951-0040

д.м.н., зав. каф. поликлинической терапии и общей врачебной практики

Russian Federation, Kazan

References

  1. ВОЗ. Гепатит С. [WHO. Hepatitis C (In Russ.)] https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c
  2. Gardenier D, Olson MC. Hepatitis C in 2019: Are We There Yet? J Nurse Pract. 2019;15(6):415-9. doi: 10.1016/j.nurpra.2018.12.009
  3. The Viral Hepatitis Prevention Board. Viral Hepatitis. 2011;19(1). https://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_Newsletters/vhv19n2.pdf
  4. Пименов Н.Н., Вдовин А.В., Комарова С.В. и др. Актуальность и перспективы внедрения в России единого федерального регистра больных вирусными гепатитами В и С. Терапевтический архив. 2013;85(11):4-9 [Pimenov NN, Vdovin AV, Komarova SV, et al. The relevance and prospects of introducing a uniform federal register of patients with viral hepatitis B and C in Russia. Therapeutic Archive. 2013;85(11):4-9 (In Russ.)].
  5. ITPCru. Долгие проводы. Результаты мониторинга закупок препаратов для лечения гепатита С в России в 2017 году. Санкт-Петербург: Коалиция по готовности к лечению, 2018 [ITPCru. Long farewell. Results of monitoring the procurement of drugs for the treatment of hepatitis C in Russia in 2017. St Petersburg: Treatment Preparedness Coalition, 2018 (In Russ.)]
  6. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122-32. doi: 10.1038/nrgastro.2016.176
  7. Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1):3-14. doi: 10.1177/2049936115585942
  8. Ferri C, Ramos-Casals M, Zignego AL, et al., ISG-EHCV coathours. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):114-60. doi: 10.1016/j.autrev.2016.09.006
  9. Санитарно-эпидемиологические правила. СП 3.1.3112-13. Профилактика вирусного гепатита С. 2014 [Sanitary and epidemiological rules. SP 3.1.3112-13. Prevention of viral hepatitis C. 2014 (In Russ.)].
  10. Министерство здравоохранения РФ. Клинические рекомендации. Хронический вирусный гепатит С (ХВГС) у взрослых. 2016 [Ministry of Health of the Russian Federation. Clinical guidelines. Chronic viral hepatitis C (HVHS) in adults. 2016 (In Russ.)].
  11. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026
  12. The Boston Consulting Group. Road to elimination: barriers and best practices in hepatitis C management. 2017.
  13. McGowan CE, Monis A, Bacon BR, et al. Fried. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57(4):1325-32. doi: 10.1002/hep.26246
  14. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic Infection with Hepatitis C Virus in Patients with Elevated or Persistently Normal Serum Alanine Aminotransferase Levels: Comparison of Hepatic Histology and Response to Interferon Therapy. J Infect Dis. 2000;182(6):1595-601.
  15. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999;29(2):590-6.
  16. ФБУЗ «Центр гигиены и эпидемиологии в Челябинской области». Анализ динамики наркомании, хронического алкоголизма и алкогольных психозов по показателям социально-гигиенического мониторинга в Челябинской области за 2014 г. 2014 [Federal Budgetary Healthcare Institution «Center for Hygiene and Epidemiology in Chelyabinsk Oblast». Analysis of the dynamics of drug addiction, chronic alcoholism and alcoholic psychoses by indicators of social and hygienic monitoring in Chelyabinsk Oblast’ for 2014. 2014 (In Russ.)].
  17. Sturm D, Gurevitz SL, Davidson C, et al. Bane of Baby Boomers. Clin Rev. 2014;24(11):24-32.
  18. Southern WN, Drainoni ML, Smith BD, et al. Physician nonadherence with a hepatitis C screening program. Qual Manag Health Care. 2014;23(1):1-9. doi: 10.1097/QMH.0000000000000007
  19. Министерство здравоохранения Челябинской области. О маршрутизации взрослых пациентов с парентеральными вирусными гепатитами в Челябинской области. 2016 [Ministry of Health of Chelyabinsk Oblast’. On routing of adult patients with parentetal viral hepatitis in Chelyabinsk Oblast’. 2016 (In Russ.)].
  20. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.
  21. The International Liver Congress 2018 Abstract Book – EASL – The Home of Hepatology. European Association for the Study of the Liver. https://easl.eu/publication/the-international-liver-congress-2018-abstract-book/
  22. Hepatitis C. Questions and Answers. CDC. https://www.cdc.gov/hepatitis/hcv/cfaq.htm
  23. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году. 2018 [Kaprin AD, Starinskii VV, Petrova GV. Malignant neoplasms in Russia in 2017. 2018 (In Russ.)].
  24. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6(1):79-84. doi: 10.14218/JCTH.2017.00067
  25. Mahale P, Sturgis EM, Tweardy DJ, et al. Torres. Association Between Hepatitis C Virus and Head and Neck Cancers. J Natl Cancer Inst. 2016;108(8):djw035. doi: 10.1093/jnci/djw035
  26. Adinolfi LE, Nevola R, Rinaldi L, et al. Chronic Hepatitis C Virus Infection and Depression. Clin Liver Dis. 2017;21(3):517-34. doi: 10.1016/j.cld.2017.03.007
  27. Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol. 2018;2018:6150861. doi: 10.1155/2018/6150861
  28. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51(3):729-33. doi: 10.1002/hep.23561
  29. Hepatitis C: Common, Deadly, and Curable. https://www.bcg.com/publications/2017/health-care-payers-providers-hepatitis-c-common-deadly-curable.aspx

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure: 2. Answers to the question "How many patients in the last month have you examined for hepatitis C, prescribing a test for antibodies to the hepatitis C virus?"

Download (69KB)
3. Figure: 3. Answers to the question “What are your criteria for screening patients for HCV? Check all that apply. "

Download (152KB)
4. Figure: 4. Answers to the question "Is the detection of antibodies to HCV sufficient to diagnose CHC?"

Download (54KB)
5. Figure: 5. Answers to the question "What method is used to confirm the diagnosis of CHC?"

Download (108KB)
6. Figure: 6. Answers to the question "What proportion of the patients with CHC identified by you are under the supervision of an infectious disease doctor or (if he is absent) sent you for a consultation to the Hepatology Center of the Clinic of the FGBOU HE SUSMU?"

Download (60KB)
7. Figure: 7. Answers to the question "When do you usually refer patients with hepatitis C to an infectious disease doctor?"

Download (150KB)
8. Figure: 8. Answers to the question "What is the average duration of the disease from the moment of infection to the beginning of the formation of liver cirrhosis?"

Download (68KB)
9. Figure: 9. Answers to the question "Specify the malignant diseases associated with chronic HCV infection."

Download (154KB)
10. Figure: 10. Answers to the question “What are the most common extrahepatic manifestations of chronic HCV infection? Highlight the 3 most common. "

Download (149KB)
11. Figure: 11. Answers to the question "Do you think that hepatitis C is curable?"

Download (67KB)
12. Figure: 12. Answers to the question "If yes, what is the effectiveness of modern antiviral therapy regimens?"

Download (105KB)
13. Figure: 13. Answers to the question "Why is it necessary to determine the HCV genotype?"

Download (141KB)

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies